Open AccessSurvival analysis of bevacizumab plus taxane treatment in luminal metastatic breast cancer
Author(s) -
Serafín Morales,
Ariadna Gasol Cudós,
Joel Veas Rodriguez,
Carles Canosa Morales,
Jordi Melé Olivé,
Felip Vilardell,
D.R. Sánchez Guzman,
E. Iglesias Martinez,
Antonieta Salud Salvia
Publication year - 2021
Publication title -
future science oa
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.825
H-Index - 23
ISSN - 2056-5623
DOI - 10.2144/fsoa-2020-0146
Subject(s) - bevacizumab , metastatic breast cancer , medicine , paclitaxel , oncology , breast cancer , taxane , chemotherapy , combination therapy , cancer , endocrine system , hormone
Background: The treatment of luminal metastatic breast cancer is based on endocrine therapy and chemotherapy treatment is limited to the progression of this treatment. Materials & methods: We analyzed the efficacy of treatment with bevacizumab plus paclitaxel in 43 patients with hormone receptor-positive and HER2-negative metastatic breast cancer. Discussion: Paclitaxel plus bevacizumab combination is a useful treatment in metastatic luminal breast cancer with an impressive overall survival of 31 months, similar to combination to endocrine therapy and targeted therapy in first line. In patients with hormone resistance, endocrine therapy saw worse results thus the taxol plus bevacizumab combination could be a better option. This combination does not influence the results of subsequent treatments; therefore, it could provide a good option for patients.